- Home
- NCMI vs LYEL Comparison
NCMI vs LYEL Comparison
Compare NCMI & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCMI | LYEL |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.7M | 369.4M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NCMI | LYEL |
|---|---|---|
| Price | $4.29 | $24.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $6.88 | ★ $16.67 |
| AVG Volume (30 Days) | ★ 538.4K | 36.7K |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $236,300,000.00 | $41,000.00 |
| Revenue This Year | $3.33 | N/A |
| Revenue Next Year | $13.09 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.81 | $7.65 |
| 52 Week High | $7.60 | $25.20 |
Technical Indicators
Market Signals| Indicator | NCMI | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 55.51 | 77.95 |
| Support Level | $3.81 | $16.95 |
| Resistance Level | $4.34 | $18.13 |
| Average True Range (ATR) | 0.15 | 1.69 |
| MACD | 0.05 | 0.74 |
| Stochastic Oscillator | 92.38 | 90.24 |
Price Performance
Historical ComparisonAbout NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.